دورية أكاديمية
أعرض في EDS

Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand.

التفاصيل البيبلوغرافية
العنوان: Economic Evaluation of Evusheld for Preexposure Prevention of COVID-19 in High-Risk Populations: Early Evidence from Thailand.
المؤلفون: Rattanavipapong W; Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health, 6th Floor, 6th Building, Tiwanon Rd., Muang, Nonthaburi, Thailand., Poonsiri C; Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health, 6th Floor, 6th Building, Tiwanon Rd., Muang, Nonthaburi, Thailand. chittawan.p@hitap.net., Isaranuwatchai W; Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health, 6th Floor, 6th Building, Tiwanon Rd., Muang, Nonthaburi, Thailand.; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada., Iamsirithaworn S; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand., Apakupakul J; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand., Sonthichai C; Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand., Kitphati R; Health Technical Office, Ministry of Public Health, Nonthaburi, Thailand., Teerawattananon Y; Health Intervention and Technology Assessment Programme, Department of Health, Ministry of Public Health, 6th Floor, 6th Building, Tiwanon Rd., Muang, Nonthaburi, Thailand.; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
المصدر: Applied health economics and health policy [Appl Health Econ Health Policy] 2023 May; Vol. 21 (3), pp. 511-522. Date of Electronic Publication: 2023 Mar 16.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Open Mind Journals Ltd Country of Publication: New Zealand NLM ID: 101150314 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1896 (Electronic) Linking ISSN: 11755652 NLM ISO Abbreviation: Appl Health Econ Health Policy Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Auckland, N.Z. : Open Mind Journals Ltd., c2002-
مواضيع طبية MeSH: COVID-19 Vaccines* , COVID-19*/prevention & control, Humans ; Cost-Benefit Analysis ; Thailand ; Retrospective Studies ; Quality-Adjusted Life Years
مستخلص: Background and Aims: The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-effectiveness and budget impact of introducing Evusheld (tixagevimab plus cilgavimab) for three patient groups-organ transplant, autoimmune disease, and dialysis patients, from the Thai government perspective.
Methods: A Markov decision model was developed to compare the use of Evusheld plus COVID-19 vaccines versus COVID-19 vaccines alone. The methodology followed the National HTA Guidelines of Thailand. Model input parameters were collected locally from retrospective data and from a literature review.
Results: Evusheld helped prevent COVID-19 infection, severe infection, and death in all three patient groups. Using the Thai threshold of 160,000 Thai Baht (THB) per quality-adjusted life year (QALY) gained, the only scenario found to be cost-effective was that of dialysis patients with inadequate immune response, with an incremental cost-effectiveness ratio (ICER) of 54,700 THB per QALY gained. To make a policy of Evusheld provision cost-effective in other groups, the price of Evusheld had to be lower (a reduction of 44-88% of its current price). The results of one-way sensitivity analysis indicated that the cost-effectiveness of Evusheld was sensitive to changes in the rate of infection, cost and efficacy of Evusheld, proportion of inadequate immune responses, and the probability of moving from a 'recovered' to 'susceptible' status.
Conclusion: Among three COVID-19-vaccinated immunocompromised patient populations, this study concluded that Evusheld was cost-effective for dialysis patients with inadequate immune response to the COVID-19 vaccine.
(© 2023. The Author(s).)
References: BMC Infect Dis. 2021 May 20;21(1):459. (PMID: 34016041)
BMJ. 2022 Mar 17;376:o722. (PMID: 35301227)
Int J Infect Dis. 2021 Nov;112:318-320. (PMID: 34547489)
BMJ. 2021 Dec 10;375:n3064. (PMID: 34893506)
J Med Assoc Thai. 2014 May;97 Suppl 5:S4-9. (PMID: 24964693)
Int J Infect Dis. 2022 Jan;114:252-260. (PMID: 34800687)
N Engl J Med. 2022 Jun 9;386(23):2188-2200. (PMID: 35443106)
J Infect. 2021 Mar;82(3):399-406. (PMID: 33589297)
Cell. 2022 Jul 7;185(14):2422-2433.e13. (PMID: 35772405)
Microbes Infect. 2021 May-Jun;23(4-5):104803. (PMID: 33667643)
Cancer Cell. 2022 Jun 13;40(6):590-591. (PMID: 35598602)
Lancet Rheumatol. 2022 Jul;4(7):e458-e461. (PMID: 35434653)
Nature. 2022 Aug;608(7923):603-608. (PMID: 35790190)
Transfus Med. 2021 Jun;31(3):167-175. (PMID: 33333627)
معلومات مُعتمدة: 65-006 Ministry of Public Health
المشرفين على المادة: 0 (cilgavimab and tixagevimab drug combination)
0 (COVID-19 Vaccines)
تواريخ الأحداث: Date Created: 20230317 Date Completed: 20230424 Latest Revision: 20230502
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10019402
DOI: 10.1007/s40258-023-00796-7
PMID: 36928779
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1896
DOI:10.1007/s40258-023-00796-7